$24.94
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company is headquartered in Alpharetta, Georgia and currently employs 2,287 full-time employees. The company went IPO on 2014-10-21. The company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. The company also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
Country

US

CEO

Mr. David Pacitti

IPO date

2014

Employees

2,287

ISIN

US05350V1061

Website

avanos.com

Key stats

Open

$24.94

Volume

285.32K

Market cap

$1.17B

Prev. close

$24.94

Impl / hst vl

-

Open interest

$0.00

$24.92

Day’s Range

$24.94

$11.06

52W Range

$25.49

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
1.63
P/B
1.49
Current ratio
2.48
Debt / Equity
0.04
ROE
-9.55%
Gross margin
51.70%
Income growth
-492.31%
FCF growth
-177.93

Analysts estimates

Consensus rating
Hold

The average rating from top 3 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$17.34
The top 3 analysts forecasts that 12-month price may decrease by 30.47%, with a low of $17.17 and a high of $17.85
$17.17
Low
$17.34
Avg
$17.85
High
Current price

Earnings

Q1 ‘26 revenue
$182.20M
Q1 ‘26 net income
$5.10M
Revenue
Net income
Previous EPS
$0.22
Estimate EPS
$0.17
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply